At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 143 enrolled
Drug / intervention
nab-paclitaxel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)
In Brief
A Phase 4 clinical trial evaluating nab-paclitaxel and Carboplatin for Non-Small Cell Lung Cancer and 5 related conditions. Completed, enrolled 143 participants across 55 sites.
Detailed Summary
Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subjects (≥ 70 years old) with advanced NSCLC
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer, Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Carcinoma, Large Cell, Lung Neoplasm
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartJun 2014
Primary CompletionJul 2017
TodayJul 2026
First PostedMay 30, 2014
Enrollment StartJun 9, 2014
Primary CompletionJul 14, 2017
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 12.1 years ago
Interventions
nab-paclitaxeldrug
Carboplatindrug